Corona Remedies IPO: Price, Analysis, Allotment, And GMP

Corona Remedies IPO - Company Analysis

Corona Remedies IPO, a Mainboard IPO, is a bookbuilding issue of Rs. 655.37 Cr by Corona Remedies Ltd., a pharmaceutical company that creates, produces, and markets medications for use in urology, cardiology, pain management, women's healthcare, and other therapeutic fields.

Women's healthcare, urology, cardiometabolic, pain management, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal and respiratory) were among the 71 items in the company's portfolio as of June 30, 2025.

With 2,671 medical agents dispersed over 22 states, the company's pan-India marketing and distribution network enables it to deepen its penetration in therapeutic areas, enhance its position in the IPM, and interact with hospitals and healthcare experts.

Corona Remedies IPO Details

The Corona Remedies Ltd IPO open date is from Dec 08 to Dec 10, with IPO allotment on Dec 11, refund initiation on Dec 12, 2025.

The Rs. 655.37 Cr mainline IPO comprises a wholly an offer for sale of 0.62 crore shares.

The Corona Remedies IPO listing date might be on Monday, 15 December 2025, and it will be listed at the BSE and NSE.

The Corona Remedies IPO price band is Rs. 1008 to Rs. 1062 for each Share. 

Events	Date
IPO Opening Date	December 08, 2025
IPO Closing Date	December 10, 2025
IPO Allotment Date	December 11, 2025 (Tentative)
Refund Initiation	December 12, 2025 (Tentative)
Tentative IPO Listing Date	December 15, 2025

 

Industry Outlook

If you want to apply for the IPO, click to open a Demat Account.

 

Company Financial

(Amount in Cr)

Period Ended	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	929.86	830.58	595.02
Total Income	1,202.35	1,020.93	891.10
PAT	149.43	90.50	84.93
EBITDA	245.91	161.19	135.03
Net Worth	606.34	480.41	408.52
Reserves & Surplus	545.18	419.25	347.36
Total Borrowing	62.70	134.14	2.33

 

Cash Flows

The cash flows for various activities are shown below:

(Amount in Mn)

Net Cash Flow In Multiple Activities	FY25	FY24	FY23
Net Cash Flow Operating Activities	1,904.96	1,567.58	1,027.00
Net Cash Flow Investing Activities	(838.40)	(2,666.43)	(502.45)
Net Cash Flow Financing Activities	(1,065.89)	985.45	(447.47)

 

Revenue Bifurcation 

(Source RHP)

The Objective of The Issue

The Promoters are selling their holdings, and the issue amount will not go to the company.

Click to check the IPO application status.

Listed Peers of Corona Remedies Ltd.

Company Name	Face Value (₹)	EPS (₹)	P/E (x)
Abbott India Limited	10	665.62	45.17
Alkem Laboratories Limited	2	181.11	31.39
Eris Lifesciences Limited	1	25.85	61.81
GlaxoSmithKline Pharmaceuticals Limited	10	54.76	46.87
J.B. Chemicals & Pharmaceuticals Limited	1	42.45	42.60
Mankind Pharma Limited	1	49.28	45.77
Pfizer Limited	10	167.79	29.63
Sanofi India Limited	10	179.46	24.47
Torrent Pharmaceuticals Limited	5	56.47	65.91

 

Valuation

KPI	Values
ROE	27.50%
ROCE	41.32%
Debt/Equity	0.10
RoNW	24.65%
PAT Margin	12.49%
EBITDA Margin	20.55%
PB Value	10.71

 

 

Evaluation of P/E Ratio

The company's IPO price of Rs. 1062 corresponds to a P/E multiple of 43.47x based on FY25 EPS of Rs. 24.43.

Explore the Orkla India IPO.

IPO's Strengths

• From MAT June 2022 to MAT June 2025, the firm with the second-fastest growth rate among the top 30 Indian pharmaceutical companies by domestic sales is well-positioned to take advantage of possibilities in the Indian market.

• Proven ability to create a varied portfolio in our targeted therapy areas, including "engine" brands.

• The "middle of the pyramid" target market was the focus of the pan-Indian sales network and marketing plan.

• Quality and current good production Practices-focused production facilities, with strong research and development skills, creating a range of distinctive pharmaceutical products.
  
  

IPO Weaknesses

• The corporation says it cannot guarantee that its primary raw-material suppliers will remain financially stable. Production may be disrupted and profitability may suffer if a major supplier experiences financial difficulties or ceases to provide.

• The company’s capacity to run successfully depends on the timely recovery of payments. Any delay in receivables can tighten working capital, hurting operations and cash flows.

• Risk of competition and market positioning.
  
  

Corona Remedies IPO GMP

Corona Remedies IPO GMP today is Rs. 161 as of 03 Dec 2025, while writing this information with a price band set at Rs. 1062. This suggests that the estimated listing price of the IPO could be around Rs. 1223, indicating a gain/loss of 15.16% per Share.

Corona Remedies Limited IPO Summary

IPO Opening & Closing Date	Dec 08, 2025 to Dec 10, 2025
Face Value	Rs. 10 per Share
Issue Price	Rs. 1008 to Rs. 1062
Lot Size	14 Shares
Issue Size	61,71,101 Shares (Rs. 655.37 Cr)
Offer for Sale	61,71,101 Shares (Rs. 655.37 Cr)
Fresh Issue	-
Listing At	BSE, NSE
Issue Type	Book Built Issue IPO
Registrar	Bigshare Services Pvt. Ltd.

Corona Remedies IPO Lot Size

The Corona Remedies Ltd. IPO allows retail investors to invest in a minimum and maximum of 1 Lot (14 Shares) amounting to Rs. 14868 and 13 Lots (182 Shares) amounting to Rs. 193284, respectively, while for S-HNI investors, the minimum Lot is 14 (196 Shares) amounting to Rs. 208152.

Minimum Lot Investment (Retail)	1 Lot
Maximum Lot Investment (Retail)	13 Lots
SHNI (Minimum)	14 Lots
SHNI (Maximum)	67 Lots
BHNI (Minimum)	68 Lots

Corona Remedies IPO Reservation

Institutional Share Portion	50%
Retail Investors' Share Portion	35%
Non-Institutional Shares Portion	15%

 

Corona Remedies IPO Allotment Status

To check the Corona Remedies IPO allotment status, visit the official Registrar’s website or the BSE website. Below are the website links for you.

Using BSE Website - ​BSE IPO allotment status

Promoters And Management of Corona Remedies  Ltd.

• Dr. Kirtikumar Laxmidas Mehta

• Niravkumar Kirtikumar Mehta

• Ankur Kirtikumar Mehta.

Pre-Issue Promoter Shareholding	72.50%
Post-Issue Promoter Shareholding	-

 

Corona Remedies IPO Lead Managers

• JM Financial Ltd. 

 

Dividend Policy

The company has paid a dividend of Rs. 3.70, Rs. 2.77 and Rs. 1.14 during the past three financial years.

 

Conclusion

Corona Remedies IPO offers investors exposure to a fast-growing Indian pharmaceutical company with solid financial performance, robust margins and a varied product range. However, as the offer is completely an OFS with no additional capital infusion, investors should weigh growth potential against value and sector concerns. 

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO. 

You must consult your financial advisor before making any financial decisions. 

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.